Document:

AMENDMENT TO
                    DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT

         This Amendment to the Development, License and Supply Agreement dated
July 23, 1999 (the "Agreement"), is entered into as of June 23, 2000, by and
between NaPro BioTherapeutics, Inc. a Delaware corporation ("NaPro") and Abbott
Laboratories, an Illinois corporation ("Abbott"). Any capitalized term used and
not otherwise defined herein shall have the meaning set forth in the Agreement.
All terms and conditions set forth in the Agreement that are not amended hereby
shall remain in full force and effect.

         1. Pursuant to Section 6.1.2 of the  Agreement, Abbott and NaPro hereby
amend the Development Plan in its entirety as set forth in Exhibit 1 hereto.

         2. Pursuant to Section 18.6 of the Agreement, Abbott and NaPro hereby
amend the Agreement to include the following Section 2.3.4:

         [THIS PORTION HAS BEEN REDACTED.]

         3. Pursuant to Section 18.6 of the Agreement, Abbott and NaPro hereby
delete Section 3.1.2 in its entirety.

         4. Pursuant to Section 18.6 of the  Agreement, Abbott and NaPro hereby
amend Section 3.1.3 in its entirety to read as follows:

         3.1.3  Except as otherwise may be provided in this Section 3.1, Six
Million Dollars ($6,000,000) within five (5) Business Days [THIS PORTION HAS
BEEN REDACTED.];

         5. Pursuant to Section 18.6 of the Agreement, Abbott and NaPro hereby
amend Section 3.1.4 in its entirety to read as follows:

         3.1.4  Approval/First Commercial Sale Milestones.  [THIS PORTION HAS
BEEN REDACTED.]

                3.1.4.1  [THIS PORTION HAS BEEN REDACTED.] eight million
dollars ($8,000,000) within five (5) Business Days [THIS PORTION HAS BEEN
REDACTED.]

                3.1.4.2  [THIS PORTION HAS BEEN REDACTED.] twelve million
dollars ($12,000,000) within five (5) Business Days [THIS PORTION HAS BEEN
REDACTED.];

<PAGE>

         6. Pursuant to Section 18.6 of the Agreement, Abbott and NaPro hereby
amend Section 6.2.2 by inserting the following sentence after the second
sentence in such Section:

         [THIS PORTION HAS BEEN REDACTED.]

         7. Pursuant to Section  18.6 of the Agreement, Abbott and NaPro hereby
amend the Agreement to include the following Section 8.7.2.5:

                8.7.2.5  [THIS PORTION HAS BEEN REDACTED.]

         8. Pursuant to Section 18.6 of the Agreement, Abbott and NaPro hereby
replace the second sentence of Section 9.4 with the following:

         NaPro may assist Abbott with technical marketing [THIS PORTION HAS BEEN
         REDACTED.] only at NaPro's cost and expense beginning not earlier than
         the number of months determined by the Marketing Committee following
         the First Commercial Sale of such Finished Product in the United
         States.

         9. Pursuant to Section 18.6 of the Agreement, Abbott and NaPro hereby
amend Section 10.8 in its entirety to read as follows and add a new Section
10.9:

                10.8.    Settlement. [THIS PORTION HAS BEEN REDACTED.]

                10.9.    Disposition of Funds. [THIS PORTION HAS BEEN REDACTED.]

         10.Pursuant to Section 18.6 of the Agreement,  Abbott and NaPro hereby
amend Section 15.3.2.2 in its entirety to read as follows:

                15.3.2.2 with respect to NaPro, a willful failure by NaPro to
perform any material obligations of NaPro under Article 6 and/or the Development
Plan, and/or under Article 8 and/or under Section 10.9.

         11.Pursuant to Section 18.6 of the  Agreement,  Abbott and NaPro hereby
amend Section 15.6.2 in its entirety to read as follows:

                15.6.2  [THIS PORTION HAS BEEN REDACTED.]

         12. Abbott and NaPro agree that, upon execution of this Amendment, a
press release in the form attached hereto as Exhibit 2 will be issued.

         13. From the date hereof,  any  reference to the  Agreement shall be
deemed to refer to the Agreement as amended by this Amendment.

         14. This Amendment shall be governed by the laws of the State of
Illinois, without giving effect to any choice of law or conflict of law
provisions, and any dispute arising out of or in connection with this Amendment
shall be governed by the provisions of Article 16 of the Agreement.

         15. This  Amendment  may be executed in  counterparts,  each of which
shall be deemed an original, but all of which will constitute one and the same
instrument.

                                       2
<PAGE>

         IN WITNESS WHEREOF, Abbott and NaPro have executed this Amendment
effective as of the date first set forth above.

ABBOTT LABORATORIES

By: /s/ Richard A. Gonzalez
Name:  Richard A. Gonzalez
Title: President, Hospital
       Products Division

NAPRO BIOTHERAPEUTICS, INC.

By: /s/ Gordon Link
Name:  Gordon Link
Title: Vice President
       and Chief Financial Officer

   [Signature page to Amendment to Development, License and Supply Agreement]AMENDMENT TO
                            STOCK PURCHASE AGREEMENT

         This Amendment to the Stock Purchase Agreement dated July 23, 1999 (the
"Agreement"), is entered into as of June 23, 2000, by and between NaPro
BioTherapeutics, Inc. a Delaware corporation ("NaPro") and Abbott Laboratories,
an Illinois corporation ("Abbott"). Any capitalized term used and not otherwise
defined herein shall have the meaning set forth in the Agreement. All terms and
conditions set forth in the Agreement that are not amended hereby shall remain
in full force and effect.

        1. Pursuant to Section 13(i) of the Agreement, Abbott and NaPro hereby
delete the definitions of "Second Additional Closing Date" and "Second
Additional Shares" and insert or replace, as the case may be, the following
definitions set forth in Section 1 of the Agreement as follows:

                  "Additional Closing Date" shall mean the First Additional
Closing Date.

                  "Additional Shares" shall mean the First Additional Shares.

                  "Amendment Shares" shall have the meaning set forth in Section
2(a)(iii).

                  "First Additional Closing Date" shall have the meaning set
forth in Section 2(b)(ii).

                  "Shares" means all of the Initial Shares, the Amendment
Shares, and the First Additional Shares.

         2. Pursuant to Section  13(i) of the  Agreement,  Abbott and NaPro
hereby amend the Agreement to include the following Sections 2(a)(iii) and
2(a)(iv):

         2(a)(iii) Against delivery of the purchase price therefor, NaPro hereby
sells and issues to Abbott, and Abbott hereby subscribes for and purchases,
711,111 shares of Common Stock (the "Amendment Shares"). The purchase price for
the Amendment Shares shall be $5.625 per share of Common Stock, or $4,000,000 in
the aggregate.

         2(a)(iv) Abbott hereby delivers to NaPro the payment described in
Section 2(a)(iii) by wire transfer of immediately available funds, and (ii)
NaPro hereby delivers to Abbott the duly executed and authenticated stock
certificates, representing all of the Amendment Shares to be purchased by Abbott
pursuant to Section 2(a)(iii). The certificates representing the Amendment
Shares shall bear the legend set forth in Section 13(n).

         3. Pursuant to Section 13(i) of the Agreement, Abbott and NaPro hereby
delete Section 2(b)(iii) and amend Sections 2(b)(i and 2(b)(ii) in their
entirety as follows:

         2(b)(i)      Upon the earlier of:

              [THIS PORTION HAS BEEN REDACTED.];

                                       1
<PAGE>

         then against delivery of the purchase price therefor, NaPro shall sell
         to Abbott, and Abbott shall purchase from NaPro, 888,889 Shares (the
         "First Additional Shares") at a purchase price of $5.625 per share of
         Common Stock, or $5,000,000 in the aggregate. [THIS PORTION HAS BEEN
         REDACTED.]

         2(b)(ii) Abbott and NaPro shall agree on a mutually acceptable Business
Day within the times specified in Section 2(b)(i) on which the sale and purchase
of the First Additional Shares (the "First Additional Closing Date") shall take
place. At least forty-eight (48) hours prior to the First Additional Closing
Date, NaPro shall deliver to Abbott written wire transfer instructions for the
payment of the purchase price for the First Additional Shares to be sold and
purchased pursuant to the terms of this Section 2(b), which instructions shall
include NaPro's bank name and address, ABA routing number and NaPro's account
number.

         4. Pursuant to Section 13(i) of the  Agreement,  Abbott and NaPro
hereby amend Section 2(c)(vi) in its entirety as follows:

         (vi) Certificates for the Additional Shares. NaPro shall have delivered
to Abbott valid certificates for the First Additional Shares, or the Amendment
Shares, as the case may be, registered in Abbott's name.

         5. Pursuant to Section 13(i) of the  Agreement,  Abbott and NaPro
hereby amend Section 2(d)(iv) in its entirety as follows:

         (iv)     Payment.  Abbott  shall  have  delivered  to NaPro the
applicable purchase price for the First Additional Shares, or the
Amendment Shares, as the case may be.

         6. Except as set forth on Exhibit 1 and except for such changes as have
been disclosed in NaPro's filings with the SEC after the date of the Agreement,
NaPro hereby affirms that the representations and warranties of NaPro set forth
in the Agreement are true and correct as of the date hereof. NaPro further
warrants that it has performed all obligations required to be performed by it
under the Agreement and this Amendment in connection with the issuance of the
Amendment Shares.

         7. NaPro herewith delivers to Abbott (i) a copy of the Certificate of
Incorporation of NaPro, as in effect on the date hereof, certified by the
Secretary of State of the State of Delaware, if amended since the date of the
Agreement, (ii) a certificate of the Secretary of State of the State of
Delaware, as of the most recent practicable date, as to the good standing of
NaPro, and (iii) a certificate of the Secretary of NaPro dated as of the date
hereof, certifying as to the Board Resolutions authorizing the execution and
delivery of the Agreement and this Amendment and the other transactions
contemplated hereby and thereby, and that such resolutions have not been amended
or repealed and are in full force and effect as of the date hereof.

         8. Except as set forth on Exhibit 2, Abbott hereby affirms that the
representations and warranties of Abbott set forth in the Agreement are true and
correct in all material respects as of the date hereof. Abbott further warrants
that it has performed in all material respects all obligations required to be
performed by it under the Agreement and this Amendment in connection with the
issuance of the Amendment Shares.

         9. Pursuant to Section 13(i) of the Agreement, Abbott and NaPro hereby
amend Section 5(a) by inserting the words "or an ANDA" after "NDA" in the first
sentence and by inserting the words "Amendment Shares" in place of the words
"Second Additional Shares" in the second sentence.

         10.Pursuant to Section 13(i) of the  Agreement,  Abbott and NaPro
hereby amend the first sentence of Section 6 as follows:

                 6. Certain Limitations. NaPro shall be obligated to effect
                  Demand Registrations as follows:

                                       2
<PAGE>

                  no more than two (2) Demand Registrations with respect to the
                  aggregate of the Initial Shares and the Amendment Shares, any
                  of which two (2) Demand Registrations that has not been
                  exercised shall lapse as of the First Additional Closing Date;

                   (ii) no more than two (2) Demand Registrations with respect
                  to the Shares as of the First Additional Closing Date.

         11.Pursuant to Section  13(i) of the  Agreement,  Abbott and NaPro
hereby amend Section 13(a) in its entirety as follows:

         (a) Survival. The representations and warranties set forth in this
Agreement given in connection with the purchase and sale of the Initial Shares
shall survive the consummation of the purchase and sale of the Initial Shares
and terminate at the end of the twentieth (20th) month after the date of this
Agreement. The representations and warranties set forth in this Agreement given
in connection with the purchase and sale of the Amendment Shares shall survive
the consummation of the purchase and sale of the Amendment Shares and terminate
at the end of the twentieth (20th) month after the date of the Amendment. The
representations and warranties set forth in this Agreement given in connection
with the purchase and sale of the First Additional Shares shall survive the
consummation of the purchase and sale of the First Additional Shares and
terminate at the end of the twentieth (20th) month after the First Additional
Closing Date. The covenants and agreements set forth in this Agreement shall
survive the consummation of this Agreement forever unless terminated earlier in
accordance with the terms of this Agreement.

         12. Pursuant to Section 13(i) of the Agreement, Abbott and NaPro hereby
amend the first sentence of Section 13(m)(i) in its entirety as follows: "Abbott
shall not sell or otherwise dispose of the Shares issued to it for a period of
one (1) year from the date of such issuance (as to the Initial Shares, the
Amendment Shares, and the First Additional Shares, each a "Restricted Period").

         13. From the date hereof,  any reference to the  Agreement shall be
deemed to refer to the Agreement as amended by this Amendment.

         14. This Amendment shall be governed by the laws of the State of
Delaware, without giving effect to any choice of law or conflict of law
provisions, and any dispute arising out of or in connection with this Amendment
shall be governed by the provisions of Article 12 of the Agreement.

         15. This Amendment may be executed in counterparts, each of which shall
 be deemed an original, but all of which will constitute one and the same
instrument.

                                       3
<PAGE>

         IN WITNESS WHEREOF, Abbott and NaPro have executed this Amendment
effective as of the date first set forth above.

ABBOTT LABORATORIES

By:______________________________
   Name:    Richard A. Gonzalez
   Title:   President, Hospital
            Products Division

NAPRO BIOTHERAPEUTICS, INC.

By:_______________________________
     Name:  Gordon Link
     Title: Vice President and
            Chief Financial Officer

            [Signature page to Amendment to Stock Purchase Agreement]

                                       4
<PAGE>

                                    Exhibit 1

             Changes to NaPro 7/23/99 Representations and Warranties

1.       The references to "Agreement" throughout Article 3 shall refer to the
         Agreement as amended by the Amendment.

2.       All defined terms shall be deemed amended as set forth in the
         Amendment.

3.       Capitalization of NaPro for purposes of Section 3(c)(i) is as follows:

                  As of 8am Mountain Time on June 23, 2000, the authorized
         capital stock of NaPro consists of (A) 30,000,000 shares of voting
         Common Stock, par value $.0075 per share, of which 23,333,793 shares
         are issued and outstanding and 405,885 shares are held in treasury, (B)
         1,000,000 shares of non-voting Common Stock, par value $.0075 per share
         (each share of which is convertible on disposition into voting Common
         Stock), of which 395,000 shares are issued and outstanding, and (C)
         2,000,000 shares of preferred stock, par value $.001 per share, of
         which none is issued and outstanding.

4.       The first sentence of Section 3(d)(i) shall be amended as follows:

         NaPro has timely filed all forms, reports and documents required to be
         filed by it with the Securities and Exchange Commission ("SEC") since
         January 1, 1996, and NaPro has heretofore made available to Abbott, in
         the form filed with the SEC (including any exhibits thereto): (A) the
         Annual Reports on Form 10-K of NaPro for the fiscal years ended
         December 31, 1996, December 31, 1997, December 31, 1998 and December
         31, 1999 (the "1999 Annual Report"); (B) all proxy and information
         statements relating to meetings of stockholders of NaPro (whether
         annual or special) held since Januar6y 1, 1996; and (C) all other
         reports and registration statements (including all Quarterly Reports on
         Form 10-Q and Current Reports on Form 8-K) filed by NaPro with the SEC
         since January 1, 1996 (including all amendments to each of the
         foregoing, the forms, reports and other documents referred to in
         clauses (A) through (C) being referred to in this Agreement,
         collectively, as the "NaPro Disclosure Documents").

5.       Section 3(d)(ii) shall be amended to include reference to NaPro's
         Annual Report on Form 10-K for the fiscal year ended December 31, 1999
         and the second and third sentences of Section 3(d)(ii) shall be amended
         as follows:

         "As of March 31, 2000, except as (A) set forth in the 1999 Annual
         Report; or (B) disclosed in Schedule 3(e), neither NaPro nor any of its
         consolidated subsidiaries had any material liabilities or obligations,
         secured or unsecured (whether accrued, absolute, contingent or
         otherwise). For purposes of the preceding sentence, a "material
         liability or obligation" is one that exceeds 5% of NaPro's consolidated
         assets as of December 31, 1999."

6.       Subpart (i) of Section 3(e) shall read as follows: "(i) set forth in
the 1999 Annual Report".

<PAGE>

                                    Exhibit 2

            Changes to Abbott 7/23/99 Representations and Warranties

1.       The references to "Agreement" throughout Article 4 shall refer to the
         Agreement as amended by the Amendment.

2.       All defined terms shall be deemed amended as set forth in the
         Amendment.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}]]